Switch theme
Sign up to access all valuation multiples
EirGenix Inc is engaged in the research and development of biosimilars and new drugs, as well as biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Furthermore, the company has two PIC/S GMP facilities, one for mammalian cells and one for microbial, to provide clinical trial drug and commercial drug production. Its products include CRM197 CARRIER PROTEIN, PRODUCT PIPELINE, COVID-19 ANTIGEN RAPID TEST.
2012
391
Last FY Revenue $33.7M
Last FY EBITDA -$13.0M
$549M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, EirGenix achieved revenue of $33.7M and an EBITDA of -$13.0M.
EirGenix expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EirGenix valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $33.7M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $7.3M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 22% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$13.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -39% | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$28.9M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | -86% | XXX | XXX | XXX |
| Net Profit | -$25.9M | XXX | -$23.3M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -69% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, EirGenix's stock price is TWD 63 (or $2).
EirGenix has current market cap of TWD 19.0B (or $634M), and EV of TWD 16.5B (or $549M).
See EirGenix trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $549M | $634M | XXX | XXX | XXX | XXX | $-0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, EirGenix has market cap of $634M and EV of $549M.
EirGenix's trades at 16.3x EV/Revenue multiple, and -42.4x EV/EBITDA.
Equity research analysts estimate EirGenix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EirGenix has a P/E ratio of -24.5x.
See valuation multiples for EirGenix and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $634M | XXX | $634M | XXX | XXX | XXX |
| EV (current) | $549M | XXX | $549M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 16.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -42.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -19.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -24.5x | XXX | -27.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEirGenix's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
EirGenix's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EirGenix's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for EirGenix and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -39% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 78% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 108% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EirGenix acquired XXX companies to date.
Last acquisition by EirGenix was XXXXXXXX, XXXXX XXXXX XXXXXX . EirGenix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was EirGenix founded? | EirGenix was founded in 2012. |
| Where is EirGenix headquartered? | EirGenix is headquartered in Taiwan. |
| How many employees does EirGenix have? | As of today, EirGenix has 391 employees. |
| Is EirGenix publicy listed? | Yes, EirGenix is a public company listed on ROCO. |
| What is the stock symbol of EirGenix? | EirGenix trades under 6589 ticker. |
| When did EirGenix go public? | EirGenix went public in 2016. |
| Who are competitors of EirGenix? | Similar companies to EirGenix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of EirGenix? | EirGenix's current market cap is $634M |
| Is EirGenix profitable? | Yes, EirGenix is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
